Legal & General Group
EWTX icon

Legal & General Group’s Edgewise Therapeutics EWTX Stock Holding History

Legal & General Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.82M Buy
44,688
+2,151
+5% +$74.2K ﹤0.01% 1998
2026
Q1 		$1.34M Sell
42,537
-10,210
-19% -$294K ﹤0.01% 2047
2025
Q4 		$1.31M Sell
52,747
-3,194
-6% -$64.1K ﹤0.01% 2132
2025
Q3 		$907K Buy
55,941
+3,634
+7% +$51.5K ﹤0.01% 2269
2025
Q2 		$686K Buy
52,307
+1,959
+4% +$28.2K ﹤0.01% 2349
2025
Q1 		$1.11M Buy
50,348
+56
+0.1% +$1.47K ﹤0.01% 2151
2024
Q4 		$1.34M Buy
50,292
+6,635
+15% +$211K ﹤0.01% 2143
2024
Q3 		$1.17M Buy
43,657
+4,405
+11% +$87.6K ﹤0.01% 2181
2024
Q2 		$707K Buy
39,252
+10,761
+38% +$188K ﹤0.01% 2305
2024
Q1 		$520K Buy
28,491
+11,834
+71% +$188K ﹤0.01% 2410
2023
Q4 		$182K Buy
16,657
+13,127
+372% +$92.2K ﹤0.01% 2713
2023
Q3 		$20.2K Sell
3,530
-540
-13% -$3.67K ﹤0.01% 3022
2023
Q2 		$31.5K Buy
4,070
+436
+12% +$3.68K ﹤0.01% 2955
2023
Q1 		$24.2K Hold
3,634
– – ﹤0.01% 3016
2022
Q4 		$32.5K Buy
3,634
+1,060
+41% +$9.94K ﹤0.01% 3031
2022
Q3 		$25K Buy
2,574
+58
+2% +$586 ﹤0.01% 3147
2022
Q2 		$20K Sell
2,516
-2,122
-46% -$16K ﹤0.01% 3235
2022
Q1 		$44K Sell
4,638
-13
-0.3% -$167 ﹤0.01% 3021
2021
Q4 		$71K Buy
4,651
+2,786
+149% +$50.1K ﹤0.01% 2971
2021
Q3 		$31K Hold
1,865
– – ﹤0.01% 3113
2021
Q2 		$40K Buy
+1,865
New +$51K ﹤0.01% 3021

Other funds holding EWTX

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Legal & General Group's EWTX Position: Q2 2026 in Review

Legal & General Group increased its Edgewise Therapeutics (EWTX) stake by 5.1% in Q2 2026, buying an estimated $74.2K and bringing the position to 44,688 shares worth $1.82M. The position accounts for ﹤0.01% of the portfolio, ranked #1998.

Legal & General Group first reported a position in EWTX in Q2 2021 and has held it in 21 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Legal & General Group held 44,688 shares of Edgewise Therapeutics worth $1.82M as of Q2 2026.
  • Legal & General Group bought 2,151 Edgewise Therapeutics shares in Q2 2026, an estimated $74.2K.
  • Edgewise Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1998 holding.
  • Legal & General Group first reported a position in Edgewise Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.